Tritace - the description, contraindications, application

The latin name: Tritace

Tritace Pharmacological groups: Inhibitors

Tritace Working substance: Ramipril

Tritace Application: the Arterial hypertension, a heart failure in the postmyocardial infarction period (at clinically stable state).

Tritace Contraindications: Hypersensitivity, a hypotension, the serious renal failure, the expressed hyperkalemia, pregnancy, a feeding a breast.

Tritace Restrictions to application: the Estimation of a parity risk - advantage is necessary in the following cases: a Quincke's disease in an anamnesis, serious autoimmune disease (a systemic lupus erythematosus, a scleroderma, etc. systemic collagenouses), a suppression of an osteal brain (a leukopenia, a thrombocytopenia), failure of the coronary or cerebral circulation, an obliterating atherosclerosis of the bottom extremities, an aortal, mitral stenosis or other. The obstructive changes complicating outflow of a blood from heart, bilateral stenosis of renal arterias or stenosis of an arteria of a unique kidney, presence of the replaced kidney, hepatitis, chronic obstructive diseases mild, a diabetes, serious renal failure (the level of a serumal creatinine is higher 300 micromole/litre or 3,5 milligram/deciliters) and a hyperkalemia (5,5 millimole/litre), a hyponatremia or restriction of a sodium in a diet, carrying out of dialysis procedures is higher, than the general anaesthesia and surgical interventions, a deaquation of an organism, children's (safety and efficiency are not determined) and advanced age.

Tritace Application at pregnancy and a feeding a breast: It counterindicative at pregnancy. For the period of treatment it is necessary to stop thoracal feeding.

Tritace Side effects: From the side of cardiovascular system and a blood (a hemopoiesis, a hemostasis): a hypotension (10,7 %), including postural (2,2 %), a stenocardia (2,9 %), a syncope (2,1 %), a heart failure (2 %), a myocardial infarction (1,7 %), a vertigo (1,5 %), a pain in a thoracal cell (1,1 %), less than in 1 % - an arrhythmia, palpitation, a hemocatheretic anemia, a pancytopenia, a thrombocytopenia, an eosinophilia, an agranulocytosis; a vasculitis. From the side of bodies of the GASTROINTESTINAL TRACT: a nausea (2,2 %), a vomiting (1,6 %), a diarrhea (1,1 %), less than in 1 % - dryness in oral cavities or rising of a salivation, an anorexia, a dyspepsia, a dysphagia, a constipation, an abdominal pain, a gastroenteritis, a pancreatitis, a hepatitis, infringement of function of a liver (a cholestatic icterus, a fulminant necrosis of a liver with a lethal outcome), change of a level of transaminases. From the side of nervous system and sense organs: Giddiness (4,1 %), headache (1,2 %), asthenia (0,3 %), less than in 1 % - infringements, an amnesia, a sleepiness, cramps, depression, frustration of dream, a neuralgia, a neuropathy, a paresthesia, a tremor, dropping of hearing, infringement of vision. From the side of respiratory system: barren tussis (7,6 %), infections of the top respiratory paths, less than in 1 % - a dyspnea, a pharyngitis, a sinusitis, a rhinitis, a tracheobronchitis, a laryngitis, a bronchospasm. From the side of genitourinary system: infringement of function of kidneys (1,2 %), less than in 1 % - a proteinuria, an oliguria, edemas; an impotency. From the side of integuments: a urticaria, a prurigo, an eruption, a polymorphic erythema, a photosensitization. Other: Less than in 1 % - decrease of mass of a body, anaphylactoid reactions, rising of a level of a urea nitrogen and a creatinine, a Quincke's disease (0,3 %), an arthralgia / arthritis, a myalgia, a fever, rising of a titre of antinuclear antibodies, a hyperkalemia, change of activity of enzymes, concentration of a bilirubin, uric acid, a glucose.

Tritace Interaction: Effects strengthen antihypertensives, including beta - adrenoblockers, including at an appreciable systemic adsorption from ophthalmologic forms, diuretic agents, opioid analgesics, agents for a narcosis, alcohol, weaken - estrogens, the NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, sympathomimetics. Will potentiate hypoglycemic effect of the peroral antidiabetic drugs, oppressing action of alcohol on the CNS. Reduces the secondary hyperaldosteronism and a hypokalemia caused by diuretics. Rises a plasma level of digoxin and a lithium (enlarges a toxicity). Potassium-sparing diuretics, cyclosporines, pharmaceuticals and additives, substitutes of salt, milk with the low maintenance of salts enlarge risk of development of a hyperkalemia. The agents rendering action, rise risk of development of a neutropenia and-or an agranulocytosis with a lethal outcome.

Tritace Overdosage: Signs: an acute arterial hypotension, infringement of a cerebral circulation, a Quincke's disease, a myocardial infarction, tromboembolic episodes. Treatment: decrease of a dose or a complete cancellation of a drug; a gastric lavage, translation of the patient in a horizontal position, carrying out of actions on augmentation the BLOOD VOLUME (introduction of an isoosmotic solution of a sodium of Sodium chloridum, decantation of other blood-substituting liquids), symptomatic therapy: Epinephrinum (subcutaneous or intravenously), Hidrocortizonum (intravenously), antihistaminics.

Tritace Way of application and dose: Inside, at a hypertension - an initial dose - 2,5 mg of 1 times day, at long therapy - 2,5-20 milligram/day in 1-2 receptions. At a heart failure in the postmyocardial infarction period in an initial dose on 2,5 mg 2 times day; in case of an inefficiency - on 5 mg 2 times day, at the expressed hypotension or on a background of diuretics - on 1,25 mg 2 times day. At renal failure (a glomerular filtration less than 40 mls / mines and more than 0,22 millimole/litre) the initial dose makes a level of a creatinine 1/4 routine with gradual augmentation up to 5 milligram/day (no more).

Tritace Precautionary measures: Treatment is carried out at the regular medical control. Prior to the beginning of treatment (for 1 weeks) previous antihypertensive therapy, including diuretics it is necessary to cancel (at impossibility of a cancellation of diuretics it is necessary to reduce doses and to correct water-electrolytic balance). At patients with malignant current of a hypertension of a dose enlarge gradually, each 24 h, under the control the HELL up to achievement of maximal effect. During therapy monitoring the HELL, the constant control of a pattern of a peripheric blood (before the beginning of the treatment, the first 3-6 month of treatment and with periodic intervals further till 1 year, it is especial at patients with the raised risk of a neutropenia), a level of protein, a potassium in plasma, a urea nitrogen, a creatinine is necessary, for function of kidneys, masses of a body, keeping of a diet. At development at the patient of a hyponatremia and a dehydration correction of a regimen of dosing (decrease of doses) is necessary. At development of a cholestatic icterus and progressing of a fulminant necrosis of a liver treatment stop. It is necessary to avoid carrying out of a haemodialysis through high capacity membranes from (for example, N69), hemofiltrations or the -PHERESIS (development of an anaphylaxis or anaphylactoid reactions is possible). It is necessary to mean, that at use at patients with autoimmune diseases and sets of symptoms, the risk of development of a neutropenia is enlarged. Hyposensitizatic therapy can rise risk of development of anaphylactic reactions. It is recommended to exclude the use of alcoholic drinks during treatment. With care to apply in an operating time to drivers of vehicles and people which trade is connected to the raised concentration of attention.

Tritace Special indicatings: Sheaths can be accepted entirely or to dissolve contents in 120 ml of water or malic juice (a solution it is possible to prepare beforehand and to store within 24 h at ambient temperature or 48 h in a refrigeration cabinet).

Trading names of drugs with working substance:
Ramipril, Tritace